Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
N
Shared by NobleBlocks on Aug 1, 2022 • 12:00 AM UTC
Authors:
Robin Kate Kelley
,
Lorenza Rimassa
,
Ann-Lii Cheng
Research Assistant
AI chat, annotations, notes & similar papers
Finding related papers...
Discussions
(0)
No comments yet
Be the first to share your thoughts!
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial | NobleBlocks
